Iscoms.
The common problem for defined purified antigens or antigen determinants has been to make them immunogenic regardless of whether they are produced conventionally, produced as cloned genetechnology products or chemically synthesized. The first problem is to get the protective antigen into a submicroscopic particle where the antigen is presented in several copies, i.e. as a multimer. For some antigens it seems also necessary to enhance the immunogenicity with an adjuvant. The immunostimulating complex (iscom) was created to fulfil these criteria by assembling antigens in a multimeric form on a matrix with built-in adjuvant to form a particle. The components are held together by hydrophobic interactions. The iscom has turned out to be highly immunogenic, inducing high antibody mediated and cell-mediated immunity including cytotoxic T cell response to influenza virus. In a mouse model iscoms containing influenza virus envelope proteins induced protective immunity by one intranasal administration. Protective immunity was also induced to a retrovirus--feline leukemia virus. In a monkey model system iscoms containing gp360 of Epstein-Barr virus induced protection to induction of tumours. Iscoms have also been used as carriers for small molecules such as oligopeptides, which combination appeared to be highly immunogenic.
Department of Virology, National Veterinary Institute, Uppsala, Sweden.
B
B
Morein
D000276:Adjuvants, Immunologic; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000956:Antigens, Viral / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D000956:Antigens, Viral; D014765:Viral Vaccines